RegulatoryAffairs

The global landscape for drug regulation and development in 2026 is undergoing its most significant transformation in decades, driven by a massive legislative overhaul in Europe and the full implementation of pricing and transparency laws in the United States. These changes are moving away from traditional, rigid submission models toward dynamic, data-driven systems that prioritize supply chain security and rapid patient access. The EU Pharmaceutical Package and Regulatory